Skip to content

Study · Case report or series · n = 1 · 2026

3 results

A Case of Oral Semaglutide for Treatment of Hepatocyte Nuclear Factor 4A Maturity-Onset Diabetes of the Young.

Grennan KN, Singh D, Chindris AM, Wilson JR

AACE endocrinology and diabetes6 Dec 2025Cited by 1 (Europe PMC)

PMID41938282 (opens in a new tab)PMCIDPMC13043482 (opens in a new tab)DOI10.1016/j.aed.2025.12.002 (opens in a new tab)PepBankPUB-41938282
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a woman with HNF4A MODY, HbA1c was 5.7% after nine months of oral semaglutide, compared with 6.1% before on glipizide and metformin.

    In plain wordsIn one woman with an inherited form of diabetes, HbA1c was 5.7% after nine months of oral semaglutide, down from 6.1% before.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c on oral semaglutide monotherapy
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    7 mg daily · oral · Nine monthsAs given in this study (human).

    Measurements

    HbA1c
    5.7%
    nine months on semaglutide
    HbA1c
    6.1%
    baseline on glipizide and metformin

    Source sentences

    Summary
    Nine months after starting semaglutide and on monotherapy with semaglutide 7 mg daily, hemoglobin A1c was 5.7%
    2 context sentences
    Summary · context
    Hemoglobin A1c was 6.1% on glipizide 5 mg daily and metformin 500 mg twice daily
    Summary · context
    A 58-year-old woman with diabetes presented for evaluation.
  2. 02HumanCase report or seriesEfficacy outcome

    In a woman with HNF4A MODY on oral semaglutide monotherapy, continuous glucose monitoring showed 98% time in range.

    In plain wordsIn one woman with an inherited form of diabetes on oral semaglutide alone, her glucose monitor showed 98% time in range.

    Peptide
    Semaglutide
    Outcome
    Not applicableTime in range on continuous glucose monitoring
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    7 mg daily · oral · Nine monthsAs given in this study (human).

    Measurements

    Time in range
    98%
    continuous glucose monitor

    Source sentences

    Summary
    and her continuous glucose monitor reported 98% time in range
    1 context sentence
    Summary · context
    A 58-year-old woman with diabetes presented for evaluation.
  3. 03HumanCase report or seriesSafety outcome

    In a woman with HNF4A MODY on oral semaglutide monotherapy, no episodes of hypoglycemia were recorded.

    In plain wordsIn one woman with an inherited form of diabetes on oral semaglutide alone, there were no episodes of low blood sugar.

    Peptide
    Semaglutide
    Outcome
    No significant changeHypoglycemia episodes
    Study

    n = 1

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    7 mg daily · oral · Nine monthsAs given in this study (human).

    Source sentences

    Summary
    with no episodes of hypoglycemia.
    1 context sentence
    Summary · context
    A 58-year-old woman with diabetes presented for evaluation.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.